PE20151588A1 - Vacuna contra el virus del dengue - Google Patents

Vacuna contra el virus del dengue

Info

Publication number
PE20151588A1
PE20151588A1 PE2015001630A PE2015001630A PE20151588A1 PE 20151588 A1 PE20151588 A1 PE 20151588A1 PE 2015001630 A PE2015001630 A PE 2015001630A PE 2015001630 A PE2015001630 A PE 2015001630A PE 20151588 A1 PE20151588 A1 PE 20151588A1
Authority
PE
Peru
Prior art keywords
dengue virus
against dengue
vaccine against
immune response
adjuvant
Prior art date
Application number
PE2015001630A
Other languages
English (en)
Inventor
Benoit Baras
Dirk Gheysen
Isabelle Solange Lucie Knott
Jean-Paul Prieels
Jean-Francois Toussaint
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42174405&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20151588(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of PE20151588A1 publication Critical patent/PE20151588A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55583Polysaccharides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente descripcion se refiere a composiciones inmunogenicas que inducen una respuesta inmune contra el virus del dengue. Mas especificamente, se refiere a vacunas del virus del dengue inactivado que incluyen un adyuvante. Las composiciones descritas en la presente memoria incluyen un adyuvante sin aluminio capaz de promover una respuesta inmune Th1. Tambien se describen metodos para su uso, por ejemplo, en la formulacion de medicamentos para la prevencion o el tratamiento de enfermedades producidas por el virus del dengue
PE2015001630A 2009-02-17 2010-02-16 Vacuna contra el virus del dengue PE20151588A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15306009P 2009-02-17 2009-02-17

Publications (1)

Publication Number Publication Date
PE20151588A1 true PE20151588A1 (es) 2015-11-18

Family

ID=42174405

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2015001630A PE20151588A1 (es) 2009-02-17 2010-02-16 Vacuna contra el virus del dengue
PE2011001431A PE20110992A1 (es) 2009-02-17 2010-02-16 Composicion inmunogenica que comprende un antigeno del virus del dengue

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2011001431A PE20110992A1 (es) 2009-02-17 2010-02-16 Composicion inmunogenica que comprende un antigeno del virus del dengue

Country Status (23)

Country Link
US (2) US9265821B2 (es)
EP (1) EP2398821B1 (es)
JP (2) JP6058266B2 (es)
KR (1) KR101738704B1 (es)
CN (1) CN102395600B (es)
AR (1) AR075437A1 (es)
AU (1) AU2010215595A1 (es)
BR (1) BRPI1011224A2 (es)
CA (1) CA2752809A1 (es)
CL (1) CL2011001993A1 (es)
CO (1) CO6551750A2 (es)
DO (1) DOP2011000268A (es)
ES (1) ES2649020T3 (es)
IL (1) IL214385A (es)
MX (1) MX338898B (es)
NZ (1) NZ700477A (es)
PE (2) PE20151588A1 (es)
PH (1) PH12015501637A1 (es)
SG (2) SG173194A1 (es)
TW (2) TWI528972B (es)
UY (1) UY32457A (es)
WO (1) WO2010094663A1 (es)
ZA (1) ZA201105656B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
ES2458355T3 (es) 2010-09-01 2014-05-05 Novartis Ag Adsorción de inmunopotenciadores sobre sales metálicas insolubles
BR112013022397A2 (pt) * 2011-03-02 2017-09-26 Derek O’Hagan vacinas combinadas com doses menores de antígeno e/ou adjuvante
KR20140033171A (ko) * 2011-05-26 2014-03-17 글락소스미스클라인 바이오로지칼즈 에스.에이. 비활성화된 뎅기 바이러스 백신
JP6345603B2 (ja) 2012-03-08 2018-06-20 ノバルティス アーゲー 追加免疫ワクチンのアジュバント化された処方物
BE1024160B9 (fr) 2015-12-22 2017-12-06 Glaxosmithkline Biologicals Sa Formulation immunogène
CA3022603A1 (en) * 2016-05-10 2017-11-16 Najit Technologies, Inc. Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process
MX2018013640A (es) * 2016-05-16 2019-08-01 Infectious Disease Res Inst Liposomas pegiladas y metodos de uso.
CA3045563C (en) 2016-12-23 2022-05-03 Intervet International B.V. Combination vaccine for swine
CN111315406A (zh) * 2017-09-08 2020-06-19 传染病研究所 包括皂苷的脂质体调配物及其使用方法
CN112601815A (zh) * 2018-08-27 2021-04-02 迈凯恩技术有限公司 使用永生化单核细胞和诱导细胞的抗感染药物、疫苗等的评价方法
CN111150849A (zh) * 2020-04-02 2020-05-15 广州隽沐生物科技股份有限公司 一种组合物及其制备方法及其应用
CN114377122B (zh) * 2022-01-18 2023-04-07 四川大学 一种基于四面体框架核酸的复合佐剂、mRNA疫苗及其制备方法和用途
WO2023147342A2 (en) * 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ES2109685T5 (es) 1993-03-23 2005-09-01 Smithkline Beecham Biologicals S.A. Composiciones para vacunas que contienen monofosforil-lipido a 3-o-desacilado.
EP0729473B1 (en) 1993-11-17 2000-08-23 OM Pharma Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US6254873B1 (en) * 1995-04-17 2001-07-03 The United States Of America As Represented By The Secretary Of The Army Inactivated dengue virus vaccine
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6846489B1 (en) 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
GB9718901D0 (en) * 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
AU1145699A (en) * 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
SK18602000A3 (sk) 1998-06-08 2001-07-10 Sca Emballage France Obal umožňujúci rýchle vyrovnanie
AU761396B2 (en) 1998-06-30 2003-06-05 Om Pharma Novel acyl pseudodipeptides, preparation method and pharmaceutical compositions containing same
DE69935606T9 (de) * 1998-10-16 2021-03-11 Glaxosmithkline Biologicals S.A. Adjuvanzsysteme und impfstoffe
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
DE60041250D1 (de) 1999-03-26 2009-02-12 Us Army Multivalenter dengue-virus impfstoff
EP1165756A2 (en) 1999-03-26 2002-01-02 Walter Reed Army Institute of Research Adaptation of virus to vertebrate cells
HU229255B1 (en) * 1999-04-19 2013-10-28 Smithkline Beecham Biolog Vaccines
AU1581400A (en) 1999-12-22 2001-07-03 Om Pharma Acyl pseudopeptides bearing a functionalised auxiliary spacer
DK1402075T3 (da) 2001-05-22 2013-02-11 Us Gov Nat Inst Health Udvikling af egnede mutationer til svækkelse af dengue-vira samt kimære dengue-vira
GB0304799D0 (en) 2003-03-03 2003-04-09 Glaxosmithkline Biolog Sa Novel method
WO2008039171A2 (en) 2005-08-08 2008-04-03 Oregon Health & Science University Inactivating pathogens with hydrogen peroxide for vaccine production
JP4828189B2 (ja) * 2005-09-14 2011-11-30 雅美 森山 分泌型IgA及びIgG抗体誘導剤
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
FR2896162B1 (fr) * 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
ES2397714T3 (es) 2006-10-12 2013-03-08 Glaxosmithkline Biologicals S.A. Vacuna que comprende un adyuvante de emulsión de aceite en agua
EP2294192A4 (en) * 2008-06-09 2011-11-23 Jolla Inst Allergy Immunolog COMPOSITIONS AND METHODS OF TREATMENT AND VACCINATION AGAINST DENGUE VIRUS (DV)

Also Published As

Publication number Publication date
PE20110992A1 (es) 2012-02-12
JP2015221803A (ja) 2015-12-10
US20160120972A1 (en) 2016-05-05
CN102395600B (zh) 2015-03-25
TW201517915A (zh) 2015-05-16
WO2010094663A1 (en) 2010-08-26
BRPI1011224A2 (pt) 2016-03-15
US20110318407A1 (en) 2011-12-29
KR101738704B1 (ko) 2017-06-08
PH12015501637A1 (en) 2019-12-11
JP6058266B2 (ja) 2017-01-11
CO6551750A2 (es) 2012-10-31
JP6104988B2 (ja) 2017-03-29
SG173194A1 (en) 2011-09-29
JP2012517979A (ja) 2012-08-09
EP2398821B1 (en) 2017-08-30
CA2752809A1 (en) 2010-08-26
AU2010215595A1 (en) 2011-08-25
CN102395600A (zh) 2012-03-28
MX2011008649A (es) 2011-09-06
NZ700477A (en) 2016-04-29
US9265821B2 (en) 2016-02-23
UY32457A (es) 2011-01-31
KR20110132379A (ko) 2011-12-07
IL214385A0 (en) 2011-09-27
SG2014014385A (en) 2014-04-28
AR075437A1 (es) 2011-03-30
TWI528972B (zh) 2016-04-11
IL214385A (en) 2016-11-30
EP2398821A1 (en) 2011-12-28
ZA201105656B (en) 2012-04-25
TW201043245A (en) 2010-12-16
CL2011001993A1 (es) 2012-04-09
ES2649020T3 (es) 2018-01-09
MX338898B (es) 2016-05-03
DOP2011000268A (es) 2012-07-31

Similar Documents

Publication Publication Date Title
PE20151588A1 (es) Vacuna contra el virus del dengue
CL2019003264A1 (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas. (divisional solicitud 201703151)
CO6331297A2 (es) Composiciones adyuvantes novedosas
EP4233898A3 (en) Influenza mrna vaccines
BR112012020839A2 (pt) vacinas para uso na profilaxe e tratamento de doença de vírus da influenza
BR112017013891A2 (pt) composições imunogênicas para uso em vacinas pneumocócicas
CR10559A (es) Vacuna de influenza
GT201500005A (es) Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue
CL2017001961A1 (es) Vacuna bivalente contra el virus de gripe porcina
AR102547A1 (es) Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
CL2016002276A1 (es) Composiciones tópicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad
UY32208A (es) Uso de antigeno de mycoplasma bovis
MX2015007753A (es) Composicion de vacunas para sujetos intactos.
AR080313A1 (es) Composiciones de virus de moquillo canino (cdv) recombinante y sus usos
CL2019001200A1 (es) Vacuna contra el parvovirus porcino y el virus del síndrome respiratorio reproductivo porcino y métodos de producción de esta.
BR112017004197A2 (pt) composições de vacina contra doenças do vírus da dengue
AR108829A1 (es) Vacuna contra virus de bronquitis infecciosa
NZ731659A (en) Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
BR112015021523A8 (pt) composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis
MX347911B (es) Vacuna contra virus de diarrea viral de bovinos.
ECSP12011951A (es) Uso de una fuente de l3 y/o l5 como vacuna o como diagnóstico para una enfermedad parasitaria
BR112012014689A2 (pt) composição de vacina
BR112014023283A8 (pt) Composição imunogênica, segunda composição imunogênica, e, método para prevenção e/ou tratamento contra doença influenza
BR112016012435A8 (pt) vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2

Legal Events

Date Code Title Description
FD Application declared void or lapsed